Biological Reconstitution Through Intein–Driven Gene Expression
We are a biotech start-up, based in Basel, Switzerland, developing a specialized platform for large Adeno-Associated Virus (AAV) -based therapies enabled by split-intein protein engineering and zebrafish translational screening.
FOUNDERS
Dr. Yury Makhankov
MD, Ph.D, Medical Affair
LinkedIn
Yury, Co-Founder of BRIDGE, drives clinical and medical strategy in rare diseases to accelerate access, strengthen evidence, and improve patient outcomes globally.
Santoro Di Franco
Professional MSc in Foreign Trade, BA in International Freight Forwarding & Logistics
LinkedIn
Santoro, Co-Founder of BRIDGE, specializes in building and scaling strategic partnerships in health innovation, connecting stakeholders to drive execution-focused, impactful collaborations.
Dr. Avisek Ghose
Ph.D Biophysics
LinkedIn
Avisek, Co-Founder of BRIDGE, drives market access and commercialization strategies to help innovative healthcare solutions reach patients faster and scale sustainably.
INFERRE HEALTHCARE 